➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Merck
Harvard Business School
Medtronic

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

CLORAZEPATE DIPOTASSIUM - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for clorazepate dipotassium and what is the scope of patent protection?

Clorazepate dipotassium is the generic ingredient in four branded drugs marketed by Able, Am Therap, Aurolife Pharma Llc, Dava Pharms Inc, Gd Searle Llc, Mylan, Purepac Pharm, Quantum Pharmics, Usl Pharma, Warner Chilcott, Watson Labs, Recordati Rare, Lederle, Sun Pharm Inds Ltd, Taro, and Alra, and is included in sixty NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for clorazepate dipotassium. Four suppliers are listed for this compound.

Drug Prices for CLORAZEPATE DIPOTASSIUM

See drug prices for CLORAZEPATE DIPOTASSIUM

Recent Clinical Trials for CLORAZEPATE DIPOTASSIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ranbaxy Laboratories LimitedN/A

See all CLORAZEPATE DIPOTASSIUM clinical trials

Pharmacology for CLORAZEPATE DIPOTASSIUM
Drug ClassBenzodiazepine
Medical Subject Heading (MeSH) Categories for CLORAZEPATE DIPOTASSIUM

US Patents and Regulatory Information for CLORAZEPATE DIPOTASSIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Quantum Pharmics CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071549-001 Sep 12, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Aurolife Pharma Llc CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 072514-001 May 11, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071510-001 Oct 19, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLORAZEPATE DIPOTASSIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Recordati Rare TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-005 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Moodys
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.